Table 4 Potential improvement in adequacy of empiric coverage for ventilator-associated pneumonia at 12 h, 24 h, and 48 h using WISCA empiric regimens
WISCA empiric regimens | Percentage of VAP with documented adequate coverage by this regimen (n = 107) | Excess percentage of adequate coverage compared to retrospective cohort | ||
|---|---|---|---|---|
12 h | 24 h | 48 h | ||
Monotherapy | ||||
Ciprofloxacin | 82 (77%) | +37% | +24% | 0% |
Tobramycin | 55 (51%) | +11% | -3% | -26% |
Ceftriaxone | 59 (55%) | +15% | +2% | -22% |
Ceftazidime | 58 (54%) | +14% | +1% | -23% |
Pip.-Tazo. | 74 (69%) | +29% | +16% | -8% |
Ertapenem | 70 (65%) | +25% | +12% | -12% |
Meropenem | 91 (85%) | +45% | +32% | +8% |
Cloxacillin | 29 (27%) | -13% | -26% | -50% |
Vancomycin | 36 (34%) | -6% | -19% | -43% |
Linezolid | 36 (34%) | -6% | -19% | -43% |
Dual combination therapy | ||||
Meropenem + Vancomycin | 99 (93%) | +53% | +40% | +15% |
Ertapenem + Vancomycin | 77 (72%) | +32% | +19% | -5% |
Pip.-Tazo. + Vancomycin | 92 (86%) | +46% | +33% | +9% |
Ceftazidime + Vancomycin | 89 (83%) | +43% | +30% | +6% |
Ceftriaxone + Vancomycin | 68 (64%) | +24% | +11% | -13% |
Ciprofloxacin + Vancomycin | 101 (94%) | +54% | +41% | +17% |
Tobramycin + Vancomycin | 99 (93%) | +53% | +40% | +16% |
Ciprofloxacin + Cloxacillin | 99 (93%) | +53% | +40% | +16% |
Tobramycin + Cloxacillin | 93 (87%) | +47% | +34% | +10% |
Meropenem + Tobramycin* | 94 (88%) | +48% | +35% | +11% |
Ertapenem + Tobramycin | 93(87%) | +47% | +34% | +10% |
Pip.-Tazo. + Tobramycin* | 96 (90%) | +50% | +37% | +13% |
Ceftazidime + Tobramycin* | 79 (74%) | +14% | +21% | -3% |
Ceftriaxone + Tobramycin | 92 (86%) | +46% | +33% | +9% |
Meropenem + Ciprofloxacin* | 101 (94%) | +54% | +41% | +17% |
Ertapenem + Ciprofloxacin | 100 (93%) | +53% | +40% | +16% |
Pip.-Tazo. + Ciprofloxacin* | 102 (95%) | +55% | +42% | +18% |
Ceftazidime + Ciprofloxacin* | 100 (93%) | +53% | +40% | +16% |
Ceftriaxone + Ciprofloxacin | 99 (93%) | +53% | +40% | +16% |
Ciprofloxacin + Tobramycin | 99 (93%) | +53% | +40% | +16% |